Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Abstract

Mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization.

J Yang, J A Williams, D I Yule and C D Logsdon
Molecular Pharmacology September 1995, 48 (3) 477-485;
J Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J A Williams
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D I Yule
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C D Logsdon
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We previously reported that a mutant human m3 muscarinic acetylcholine receptor in which threonine residues at positions 550, 553, and 554 in the carboxyl terminus had been substituted with alanines showed a significant blockage of receptor down-regulation when expressed in Chinese hamster ovary-K1 cells. Because Chinese hamster ovary cells showed little receptor sequestration, in the present study we investigated further the effects of these mutations on sequestration and desensitization in human embryonic kidney (HEK) 293 cells. Wild-type and mutant receptors were transiently transfected into HEK 293 cells. The level of m3 muscarinic acetylcholine receptor expression was approximately 300 fmol/mg protein, and the transfection efficiency was approximately 30% for all receptors. Also, wild-type and mutant receptors induced similar 4-fold increases in phosphoinositide (PPI) hydrolysis and showed similar Ca2+ responses after carbachol (CCh) treatment. However, the sequestration of wild-type receptors, determined as the difference between the extent of binding of lipophilic and hydrophilic ligands, occurred in a time- and dose-dependent manner to a maximum of approximately 40% of total receptors. In contrast, sequestration was almost totally blocked in cells expressing Ala550,553 or Ala550,553,554 mutant receptors. To determine the functional significance of sequestration and investigate its relationship to receptor desensitization, cells were preincubated with CCh and then washed free of agonist and restimulated with CCh. Desensitization was manifest as a time- and concentration-dependent decrease in the ability of the second stimulation to increase PPl hydrolysis. One-hour pretreatment with 1 mM CCh decreased PPl hydrolysis by 24% for wild-type receptors but had no effect on the ability of the mutant receptors to respond to a second CCh challenge. Furthermore, inhibition of wild-type receptor sequestration by treatment with conconavalin A also blocked desensitization to a 1-hr treatment with CCh. These results suggest that sequestration may be directly involved in m3 receptor desensitization at early times. More prolonged CCh treatment (3-9 hr) reduced the PPl hydrolysis response of the mutant and the wild-type receptors, indicating that the mechanism of m3 receptor desensitization at later times involves multiple components.

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology
Vol. 48, Issue 3
1 Sep 1995
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization.
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract

Mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization.

J Yang, J A Williams, D I Yule and C D Logsdon
Molecular Pharmacology September 1, 1995, 48 (3) 477-485;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Abstract

Mutation of carboxyl-terminal threonine residues in human m3 muscarinic acetylcholine receptor modulates the extent of sequestration and desensitization.

J Yang, J A Williams, D I Yule and C D Logsdon
Molecular Pharmacology September 1, 1995, 48 (3) 477-485;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics